Identification and characterization of binding proteins for inhibin and activin in human serum and follicular fluids
- PMID: 7678220
- DOI: 10.1210/endo.132.1.7678220
Identification and characterization of binding proteins for inhibin and activin in human serum and follicular fluids
Abstract
Inhibins and activins are produced by a variety of tissues and may have important endocrine and paracrine roles in development, reproduction, and hematopoiesis. However, little is known regarding the physical properties or concentrations of inhibin and activin in biological fluids. Binding proteins for inhibin or activin in serum or at production or target sites may have important implications for restricting the bioactivity of these hormones and may alter the immunoreactivity of these molecules in biological fluids. The objective of this study was to identify inhibin- and activin-binding proteins in human serum (HS) and follicular fluid (hFF) and determine the ability of these proteins to alter biological or immunological activity. In HS, [125I]activin and inhibin bound to a protein identified as alpha 2-macroglobulin (alpha 2M) using three criteria: 1) [125I]inhibin and activin bind purified alpha 2M, but not several other serum proteins tested; 2) complexes formed by [125I]inhibin and activin in HS and in the presence of purified alpha 2M elute with similar retention times on HPLC; and 3) preadsorption of HS with alpha 2M antiserum inhibits inhibin and activin binding to this protein while antiserum directed against follistatin or other serum proteins had no effect. A small amount of a lower mol wt [125I]activin-follistatin complex was also found in HS. This complex eluted with a retention time similar to that of activin bound to purified porcine follistatin. Binding of inhibin to follistatin could not be detected in HS. In contrast, follistatin was the major binding protein of both activin and inhibin in hFF. Concentrations up to 100 micrograms/ml purified alpha 2M had no effect on the bioactivity or immunoreactivity of either inhibin or activin. In contrast, follistatin inhibited both activin-stimulated pituitary FSH release and K562 hemoglobin production as well as antiserum binding in a specific activin-A immunoassay. Follistatin did not interfere with inhibin immunodetection. These data indicate that two inhibin- and activin-binding proteins are present in different relative amounts in HS and hFF, alpha 2M, the primary binding protein in HS, did not alter inhibin or activin bio- or immunoactivity under the conditions of these experiments, while follistatin, the major binding protein in hFF, may mask activin's bio- and immunoactivities.
Similar articles
-
Alpha 2-macroglobulin is a binding protein of inhibin and activin.Endocrinology. 1993 May;132(5):2038-50. doi: 10.1210/endo.132.5.7682939. Endocrinology. 1993. PMID: 7682939
-
Follistatins and alpha 2-macroglobulin are soluble binding proteins for inhibin and activin.Horm Res. 1996;45(3-5):207-10. doi: 10.1159/000184789. Horm Res. 1996. PMID: 8964585 Review.
-
Decay of follicle-stimulating hormone-beta messenger RNA in the presence of transcriptional inhibitors and/or inhibin, activin, or follistatin.Mol Endocrinol. 1993 May;7(5):668-80. doi: 10.1210/mend.7.5.7686252. Mol Endocrinol. 1993. PMID: 7686252
-
Characterization of unique binding kinetics of follistatin and activin or inhibin in serum.Endocrinology. 1994 Aug;135(2):667-74. doi: 10.1210/endo.135.2.8033815. Endocrinology. 1994. PMID: 8033815
-
A two-site chemiluminescent assay for activin-free follistatin reveals that most follistatin circulating in men and normal cycling women is in an activin-bound state.J Clin Endocrinol Metab. 1998 Mar;83(3):851-8. doi: 10.1210/jcem.83.3.4651. J Clin Endocrinol Metab. 1998. PMID: 9506739 Review.
Cited by
-
Virtual High-Throughput Screening To Identify Novel Activin Antagonists.J Med Chem. 2015 Jul 23;58(14):5637-48. doi: 10.1021/acs.jmedchem.5b00753. Epub 2015 Jul 7. J Med Chem. 2015. PMID: 26098096 Free PMC article.
-
Interleukin-1 beta enhances and interferon-gamma suppresses activin A actions by reciprocally regulating activin A and follistatin secretion from bone marrow stromal fibroblasts.Clin Exp Immunol. 2001 Oct;126(1):64-8. doi: 10.1046/j.1365-2249.2001.01644.x. Clin Exp Immunol. 2001. PMID: 11678900 Free PMC article.
-
Proteomic identification and functional validation of activins and bone morphogenetic protein 11 as candidate novel muscle mass regulators.Mol Endocrinol. 2008 Dec;22(12):2689-702. doi: 10.1210/me.2008-0290. Epub 2008 Oct 16. Mol Endocrinol. 2008. PMID: 18927237 Free PMC article.
-
Follistatin Forms a Stable Complex With Inhibin A That Does Not Interfere With Activin A Antagonism.Endocrinology. 2023 Jan 9;164(3):bqad017. doi: 10.1210/endocr/bqad017. Endocrinology. 2023. PMID: 36718082 Free PMC article.
-
Activin receptor type 2A (ACVR2A) functions directly in osteoblasts as a negative regulator of bone mass.J Biol Chem. 2017 Aug 18;292(33):13809-13822. doi: 10.1074/jbc.M117.782128. Epub 2017 Jun 28. J Biol Chem. 2017. PMID: 28659341 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases